Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

Genevant Sciences and Arbutus Biopharma (ABUS) filed five international lawsuits seeking to enforce patents protecting their innovative LNP ...

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Genevant and Arbutus have provided evidence from tests on Moderna product samples sourced from the U.S. and Europe, which they assert contain LNPs covered by their patents. The legal actions ...

WARMINSTER, PA — Arbutus Biopharma Corporation recently announced a favorable outcome in its ongoing patent infringement ...

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic ...

Roivant Sciences portfolio company Genevant Sciences and Canada’s Arbutus Biopharma yesterday filed five international ...

BASEL, Switzerland - Genevant Sciences, a subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV), and Arbutus Biopharma Corporation (NASDAQ:ABUS), have initiated international legal actions against Moderna ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) — Genevant Sciences, a leading nucleic acid delivery company with world-class platforms ...